Zachery Reichert is an Oncology physician affiliated with University of Michigan. OpenAlex indexes 166 publications with 1,923 citations (h-index 22); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1500 E Medical Center Dr
Ann Arbor, MI 481095000
Telephone
734-936-4000Provider last certified this registry record 26 Oct 2020.
Clinical trials
- Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Sponsor: University of Michigan Rogel Cancer Center
- Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)
Sponsor: University of Michigan Rogel Cancer Center
- Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)
Sponsor: University of Michigan Rogel Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Scientific Affairs, LLCProgram year20253 payments
- Janssen Research & Development, LLCProgram year20243 payments
- Janssen Scientific Affairs, LLCProgram year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
55.6%Cytochrome P450 17A1 Inhibitor32.9%Abiraterone Acetate100%Part D≥54 patientsAndrogen Receptor Inhibitor16.6%Xtandi75%Bicalutamide25%Part D≥27 patients+ 2 more classes in this area
Metabolism & gastrointestinal
19.4%Corticosteroid16.9%Prednisone100%Part D≥70 patientsSerotonin-3 Receptor Antagonist2.5%Ondansetron Hcl100%Part D≥15 patientsNervous system
10.8%Opioid Agonist5.3%Morphine Sulfate Er41%Morphine Sulfate34%Oxycodone Hcl25%Part D<11 patientsPhenothiazine3.8%Prochlorperazine Maleate100%Part D≥21 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4
Journal of Clinical Oncology
2026 - NCCN Guidelines® Insights: Testicular Cancer, Version 2.2025
Journal of the National Comprehensive Cancer Network
2025 - Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma
New England Journal of Medicine
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Moshe Talpaz, MD
University of Michigan
William Herman, MD
University of Michigan
Max Wicha, MD
University of Michigan
Dinesh Khanna, MD
University of Michigan
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”